Abstract
This is a controlled efficacy study with doxazosin (4 mg/day) in the long-term management of 64 ambulatory patients with benign prostatic hyperplasia (BPH). Doxazosin was given for 72 weeks and is being continued. Twenty-three controls were treated with prazosin (Minipress-4 mg/day) for 24 weeks, after which the results were similar in both the doxazosin (group 1) and prazosin (group 2) patients. Maximal and mean urethral flow increased by 44.8% and 43.5%, retention volume fell by 72.0% and 74.5%, obstructive symptoms decreased by 89.6% and 92.8% and irritation was alleviated by 81.6% and 85.0% in groups 1 and 2, respectively. Global score improved by 81.5% in group 1 and by 93.0% in group 2. Both doxazosin and prazosin produced good and similar therapeutic results. Doxazosin has the advantage of more convenient dosing (once daily) and unlike prazosin it does not produce orthostatic blood pressure falls; it is less toxic and better tolerated.
Similar content being viewed by others
References
Boyarsky, S., Jones, G., Paulson, D. F., Prout, G. R. Jr.: A new look on bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy.Trans. Am. Assoc. Genito-Urin. Surg., 68, 29 (1977).
Chapple, C. R., Aubry, M. L., James, S., Greengrass, P. M., Burnstock, G., Turner-Warwick, R. T., Milroy, E. J., Davey, M. J.: Characterization of human prostatic adrenoceptors using pharmacologic receptor binding and localization.Br. J. Urol., 63, 487 (1989).
Chodera, A., Herman, Z. S. (eds): Clinical Pharmacology (in Polish). PZWL, Warszawa 1986.
Dutkiewicz, S.: Guidelines for the diagnosis and qualification for treatment of benign prostatic hypertrophy.Ter. Leki, 20/42 (2–3), 29 (1992).
Dutkiewicz, S., Filipek, M.: Prazosin concentration monitoring in the treatment of prostatic adenoma.Int. Urol. Nephrol., 23, 143 (1991).
Dyniewska-Adamska, H.: Doxazosin—a hypotensive drug.Probl. Terap. Monitor., 2/3, 73 (1991).
Fabricius, P. G., Weizert, P., Dunzendorfer, U., Hannaford, J. M., Maurath, C.: Efficacy of once-a-day Terazosin in benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled clinical trial.The Prostate, Suppl. 3, 85 (1990).
Lepor, H.: Alpha-1-adrenergic blockers in the medical management of benign prostatic hyperplasia.Curr. Opin. Urol., 2, 26 (1992).
Lepor, H., Shapiro, E.: Characterization of alpha-1-adrenergic receptors in human benign prostatic hyperplasia.J. Urol., 132, 1226 (1984).
Shapiro, E., Lepor, H.: Smooth muscle content and neuroendocrine physiology of human benign prostatic hyperplasia.Curr. Opin. Urol., 2, 22 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dutkiewicz, S., Witeska, A. Doxazosin—An alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part one). International Urology and Nephrology 27, 311–318 (1995). https://doi.org/10.1007/BF02564768
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02564768